On 27 March 2019, Phosphagenics announced that Dr. Ross Murdoch will step down from his role as Chief Executive Officer, and becoming a Non-Executive Director effective April 1, 2019. The Board had agreed to the early release from his six-month notice period, in exchange for Dr. Murdoch releasing Phosphagenics from paying any outstanding contractual entitlements. Dr. Greg Collier will assume the role of Executive Chairman from Non-Executive Chairman, effective April 1, 2019 and will be closely supported by Dr. Paul Gavin (Chief Scientific Officer) and Dr. Roksan Libinaki (GM Animal Health & Production) who will make up the Executive Management team.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 AUD | -25.00% | -14.29% | -14.29% |
05-16 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
03-25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
1st Jan change | Capi. | |
---|---|---|
-14.29% | 8.44M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.18% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- AVE Stock
- News Avecho Biotechnology Limited
- Phosphagenics Limited Announces Management Changes, Effective from April 1, 2019